These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. [Chemotherapy of metastatic cancer of the bladder. Apropos of 50 patients treated with M-VAC]. Beuzeboc P; Dhote R; Thiounn N; Flam T; Zerbib M; Debré B; Pouillart P Cancer Radiother; 1998 Apr; 2 Suppl 1():92s-96s. PubMed ID: 9749087 [TBL] [Abstract][Full Text] [Related]
9. [Preliminary results of a phase II randomized controlled trial comparing M-VAC and M-CAVI in patients with bladder cancer (T2-4 N0-1 M0)]. Bellmunt Molins J; Ribas A; Albanell J; Lorente Garín JA; de Torres Mateos JA; Morote Robles J; López Palacios MA; Banús Gassol JM; Casado Cobo S; Eres N; Solé Calvo LA Arch Esp Urol; 1996 Jun; 49(5):465-72. PubMed ID: 8766083 [TBL] [Abstract][Full Text] [Related]
10. Methotrexate, vinblastine, adriamycin and cisplatin (MVAC) chemotherapy for the treatment of advanced bladder carcinoma. Balbay MD; Ozen H; Uluçay S; Sahin A; Ergen A; Koçal C; Remzi D Int Urol Nephrol; 1993; 25(4):351-7. PubMed ID: 8276565 [TBL] [Abstract][Full Text] [Related]
11. [M-VAC chemotherapy for patients with lymph node metastases and/or locally advanced bladder carcinoma]. Igawa M; Ueki T; Ueda M; Okada K; Usui T; Ohnishi Y; Nakatsu H; Kume T; Kodama M; Masu C Hinyokika Kiyo; 1989 Aug; 35(8):1323-7. PubMed ID: 2683648 [TBL] [Abstract][Full Text] [Related]
12. [Two cases of urothelial cancer responsive to high-dose-intensity methotrexate vinblastine doxorubicin and cisplatin (M-VAC) therapy]. Fukuda H; Mitsumori K; Minagawa S; Kumazawa T; Tadachi K; Iinuma M; Satoh S; Satoh K; Habuchi T; Kato T Hinyokika Kiyo; 2005 Feb; 51(2):113-6. PubMed ID: 15773365 [TBL] [Abstract][Full Text] [Related]
13. [MEP (methotrexate, etoposide and cisplatin) and M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced uroepithelial cancer--a preliminary report of MEP as second line chemotherapy for recurrence after M-VAC]. Seguchi T; Nakano E; Miki T; Kondoh M; Nishimura K; Nakamura N; Okuyama A Gan To Kagaku Ryoho; 1994 Jan; 21(1):59-65. PubMed ID: 8291917 [TBL] [Abstract][Full Text] [Related]
14. [Place of chemotherapy in the treatment of invasive bladder tumors]. Pariente JL; Theodore C; Davin JL; Rischmann P; Chopin D Prog Urol; 1999 Apr; 9(2):219-24. PubMed ID: 10370944 [TBL] [Abstract][Full Text] [Related]
15. Can patient selection for bladder preservation be based on response to chemotherapy? Sternberg CN; Pansadoro V; Calabrò F; Schnetzer S; Giannarelli D; Emiliozzi P; De Paula F; Scarpone P; De Carli P; Pizzo M; Platania A; Amini M Cancer; 2003 Apr; 97(7):1644-52. PubMed ID: 12655521 [TBL] [Abstract][Full Text] [Related]
16. Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy. George L; Bladou F; Bardou VJ; Gravis G; Tallet A; Alzieu C; Serment G; Salem N Urology; 2004 Sep; 64(3):488-93. PubMed ID: 15351577 [TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant M-VAC chemotherapy and partial cystectomy for treatment of locally invasive transitional cell carcinoma of the bladder. Simon SD; Srougi M Prog Clin Biol Res; 1990; 353():169-74. PubMed ID: 2217415 [No Abstract] [Full Text] [Related]
18. [Neoadjuvant chemotherapy for invasive bladder cancer]. Kageyama Y; Kihara K Gan To Kagaku Ryoho; 2001 Nov; 28(12):1838-44. PubMed ID: 11729476 [TBL] [Abstract][Full Text] [Related]
19. Chemotherapy for advanced urothelial tract tumors: the M-VAC regimen. Sternberg CN; Yagoda A; Scher HI Prog Clin Biol Res; 1988; 277():45-51. PubMed ID: 3054909 [No Abstract] [Full Text] [Related]